‘Dartmouth’s Center for Technology and Behavioral Health Launches Collaboration with Boehringer Ingelheim to Develop Digital Health Tools to Help Patients and Providers’ (Geisel School of Medicine News- October 30, 2024 – Full Article)
Article Excerpt: The one-year collaboration, with the option for renewal, aims to combine CTBH’s pioneering research with Boehringer Ingelheim’s industry expertise. Their focus will be to create, study, and implement digital health solutions that could revolutionize how clinicians prescribe digital health tools to address mental and behavioral health conditions. This initiative, which has been years in the making, is set to officially launch this fall.
“This collaboration aims to elevate the promise of prescription digital therapeutics, which have the potential to positively impact the health and quality of life for people living with serious mental illness, as well as provide easier access to care,” said Michael Jablonski, PhD, vice president of clinical development and medical affairs at Boehringer Ingelheim. “There is a need for new mental health treatments and approaches that can address the unique needs of people living with serious mental illness. CTBH shares with us a belief in creating a deeper understanding of the drivers of serious mental illness, and this collaboration is an important step forward in the long-term journey of delivering more integrated and tailored solutions to enable better outcomes.”